How to Choose an E-Signature Platform for Life Sciences

Choosing an e-signature platform for life sciences means evaluating FDA 21 CFR Part 11 compliance, tamper-evident audit trails with hash chain verification, two-factor authentication at the point of signing (not just login), validation documentation (IQ/OQ/PQ), signature meaning capture, and long-term retention capabilities. Unlike general-purpose tools like DocuSign or Adobe Sign, platforms built for regulated industries provide these controls as core features rather than add-ons.

This guide walks through the evaluation criteria that matter for life sciences, the red flags to watch for, the questions to ask vendors, and practical considerations around cost, implementation, and migration.

Why Do Life Sciences Companies Need Specialized E-Signature Tools?

Life sciences operates under overlapping regulatory frameworks that govern electronic records and signatures. In the US, FDA 21 CFR Part 11 sets requirements for electronic records and electronic signatures used in FDA-regulated activities. In the EU, Annex 11 of the GMP guidelines covers computerized systems. Globally, ICH guidelines influence expectations across jurisdictions.

These regulations share common themes: identity verification, audit trails, data integrity, and system validation. A general-purpose e-signature platform may handle identity verification and basic audit logging, but it's unlikely to meet the specific requirements around signature meaning, training documentation, two-factor authentication for signing, or the kind of detailed, tamper-evident audit trails that regulators expect.

The consequence of getting this wrong isn't abstract. FDA warning letters regularly cite Part 11 deficiencies. EU GMP inspections flag inadequate computerized system controls. In clinical trials, e-signature compliance issues can jeopardize data integrity and, by extension, the entire submission.

Key Evaluation Criteria

These criteria should form the backbone of your evaluation. They're listed roughly in order of regulatory importance, though all are needed for a production deployment.

1. FDA 21 CFR Part 11 Compliance

This is the threshold requirement for any US-regulated life sciences company. Part 11 mandates that electronic signatures be linked to their respective electronic records, that signed records can't be altered without detection, and that each signature includes the printed name of the signer, the date and time of signing, and the meaning of the signature (such as "approval," "review," or "authorship").

What to verify:

• Does the platform capture signature meaning as part of the signing workflow?
• Are signatures permanently linked to the specific document version that was signed?
• Does the signed record become immutable? Can it be modified after signing?
• Does the platform support biometric/behavioral signing components, or does it rely on two discrete identification components (Part 11 Section 11.200)?
• Is there a mechanism to detect record alteration (cryptographic hashing)?

Certivo captures signature meaning at the point of signing, links each signature to a specific document hash, and makes signed records immutable. Every signature includes the signer's full name, the timestamp, and the declared meaning, meeting the core Part 11 requirements.

2. Audit Trail Capabilities

Audit trails are the single most scrutinized feature in regulatory inspections. Part 11 Section 11.10(e) requires secure, computer-generated, time-stamped audit trails to independently record the date and time of operator entries and actions. These trails must be retained for the required record retention period and must be available for FDA review.

Evaluate these specific characteristics:

• Completeness: Every action (document creation, viewing, signing, declining, delegation, voiding) must be logged
• Tamper evidence: The audit trail itself must be protected from modification. Cryptographic hash chains are the gold standard
• Independent timestamps: Timestamps should come from a trusted, independent source such as an RFC 3161 timestamp authority, not the user's local clock
• Attribution: Each entry must identify who performed the action, when, and from where (IP address, device)
• Exportability: You need to export audit trails for regulatory review in a readable format
• Retention: Audit data must be retained for the full record retention period, which in life sciences is typically the life of the product plus additional years

3. Two-Factor Authentication

Part 11 Section 11.200 requires that electronic signatures based on identification codes in combination with passwords employ at least two distinct identification components. While this technically refers to the username/password combination, modern interpretation, reinforced by data integrity guidance from FDA, EMA, and MHRA, expects additional authentication factors for signing events.

Your e-signature platform should enforce two-factor authentication at the point of signing, not just at login. Even after a user is logged in, they should re-authenticate with a second factor (such as a TOTP code) before their signature is applied. This prevents unauthorized signatures when a workstation is left unattended.

4. Validation Documentation

Any computerized system used in a GxP environment must be validated, meaning you need documented evidence that the system consistently performs as intended. For e-signature platforms, this typically means:

• A validation plan and summary report
• Installation Qualification (IQ): evidence the system is installed correctly
• Operational Qualification (OQ): evidence the system operates as specified
• Performance Qualification (PQ): evidence the system performs as intended in your environment
• User Requirement Specifications (URS) and traceability to testing

Ask vendors whether they provide validation documentation packages or IQ/OQ protocols. Some vendors include these in their enterprise offering; others leave validation entirely to the customer. A vendor that provides validation support cuts your implementation burden significantly.

5. Retention and Archival

Life sciences record retention requirements are among the longest in any industry. Clinical trial records must be retained for at least two years after the last marketing application approval or investigational drug application termination. Manufacturing records have their own retention requirements tied to product shelf life. Some records must be kept permanently.

Your e-signature platform must support these long retention periods without degrading the accessibility or integrity of signed records. Ask:

• What is the vendor's data retention policy? Will they store records for 15+ years?
• Can you export signed documents and audit trails for independent archival?
• Are documents stored in a non-proprietary format (PDF) that remains accessible long-term?

6. HIPAA and GDPR Compliance

Life sciences companies frequently handle data covered by additional privacy regulations. Clinical trial data may include protected health information under HIPAA. Studies involving EU subjects trigger GDPR obligations. Your e-signature platform needs to support compliance with these overlapping frameworks.

For HIPAA, the vendor must offer a Business Associate Agreement (BAA) and maintain HIPAA-eligible infrastructure. For GDPR, you need data processing agreements, appropriate legal bases for processing, and the ability to honor data subject access and erasure requests.

7. Integration Capabilities

An e-signature platform doesn't operate in isolation. In life sciences, it typically needs to connect with document management systems (DMS), electronic lab notebooks (ELN), quality management systems (QMS), clinical trial management systems (CTMS), and ERP systems.

Look for:

• A well-documented REST API for custom integrations
• Webhook support for event-driven workflows
• Pre-built connectors for common life sciences systems
• SSO/SAML integration for centralized identity management

Red Flags to Watch For

During vendor evaluation, certain signals should raise immediate concern:

• "We are Part 11 compliant" — No vendor can be Part 11 compliant on your behalf. Part 11 compliance is a combination of the software's capabilities, your configuration, your SOPs, and your validation. A vendor claiming blanket compliance either misunderstands the regulation or is being misleading.
• No tamper-evident audit trail — If the vendor's audit trail is a simple database log without cryptographic integrity protection, it can be modified without detection. A serious deficiency.
• No BAA available — If the vendor can't or won't sign a BAA, they shouldn't be handling any data that might contain PHI.
• Login-only 2FA — Two-factor authentication at login but not at signing leaves a gap. The signature itself must be authenticated, not just the session.
• No validation support — A vendor that provides no validation documentation and offers no IQ/OQ/PQ guidance is shifting a significant burden to your quality team.
• Proprietary document formats — If signed documents are stored in a format that requires the vendor's software to view, you have a long-term accessibility risk and a vendor lock-in problem.
• No export capability — If you can't export signed documents and audit trails in a standard format, you're dependent on the vendor for regulatory responses. That's a risk.

Questions to Ask Vendors

Use these during demos and RFI/RFP processes. The quality of the answers will quickly separate purpose-built platforms from general-purpose tools:

1. How does your platform capture and store the meaning of each signature?
2. Describe the technical implementation of your audit trail. Is it hash-chained? What hashing algorithm do you use?
3. Where are timestamps sourced from? Do you use an independent RFC 3161 timestamp authority?
4. Is two-factor authentication enforced at signing, or only at login?
5. Do you provide IQ/OQ documentation or validation packages?
6. Can we see a sample audit trail export for a completed signing workflow?
7. What's your data retention policy? Can we retain records for 15+ years?
8. Do you offer a BAA for HIPAA compliance?
9. How are documents protected from modification after signing?
10. What happens to our data if we terminate the contract? What export formats are available?
11. Describe your infrastructure. What cloud provider and region? What encryption standards?
12. Have you undergone any third-party security audits or assessments?

Total Cost of Ownership

The subscription price is only one piece of the total cost. For life sciences, the hidden costs often dwarf the license fee:

A platform with a lower sticker price that requires extensive validation work, SOP workarounds for missing features, and manual audit trail management will often cost more over its lifetime than a purpose-built solution. Certivo's pricing is designed to be transparent; what you see includes the compliance capabilities, not just the signature mechanism.

Implementation Timeline

Realistic timelines for a life sciences e-signature deployment:

1. Weeks 1-2: Requirements and vendor selection. Define your URS, evaluate vendors against the criteria above, and select a platform.
2. Weeks 3-4: Configuration and pilot. Configure the platform, set up user roles, define document templates, and run a pilot with a small group.
3. Weeks 5-8: Validation. Execute IQ/OQ/PQ protocols. This is typically the longest phase and depends on the vendor's validation support and your quality system requirements.
4. Weeks 9-10: Training and SOP finalization. Train end users, finalize SOPs, and update your quality system documentation.
5. Week 11+: Phased rollout. Start with lower-risk document types and expand to GxP-critical documents as confidence builds.

Migration Considerations

If you're migrating from an existing e-signature platform or from paper-based processes, keep these points in mind:

• Legacy document access: Export all signed documents and audit trails from your current platform before terminating the contract. Store exports in a validated archive.
• Parallel running period: Run both systems during the transition. This lets you validate the new system while maintaining business continuity.
• Re-validation is required. Moving to a new platform means a new validation effort. You can't transfer validation from one system to another.
• Change control: The migration should go through your organization's change control process, with appropriate impact assessments and approvals.
• User adoption: Don't underestimate the change management effort. Even a better platform will face resistance if the transition isn't supported with training and communication.

Making Your Decision

The right e-signature platform for life sciences reduces your regulatory burden rather than adding to it. It should make compliance the default, not something you have to engineer around. When Part 11 compliance, tamper-evident audit trails, signing-time 2FA, and proper signature meaning capture are built into the architecture, your quality and compliance teams can focus on higher-value work instead of compensating for tool gaps.

Certivo was purpose-built for this use case. Every signing event is authenticated with two-factor verification. Every audit trail is SHA-256 hash-chained with independent RFC 3161 timestamps. Signature meaning is captured at the point of signing. Documents are immutable after execution. And the platform runs on HIPAA-eligible AWS infrastructure with a BAA available for all applicable plans.

Explore our compliance documentation for detailed regulatory mapping, review our security architecture, or see our plans to find the right fit for your organization.